Buscar
Solid Biosciences Inc
SLDBAñadir a la lista de seguimiento
8.050USD
-0.440-5.18%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
792.08MCap. mercado
PérdidaP/E TTM
Más Datos de Solid Biosciences Inc Compañía
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Información de Solid Biosciences Inc
Símbolo de cotizaciónSLDB
Nombre de la empresaSolid Biosciences Inc
Fecha de salida a bolsaJan 26, 2018
Director ejecutivoCumbo (Alexander)
Número de empleados100
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 26
Dirección500 Rutherford Avenue
CiudadCHARLESTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02129
Teléfono16173374680
Sitio Webhttps://www.solidbio.com/
Símbolo de cotizaciónSLDB
Fecha de salida a bolsaJan 26, 2018
Director ejecutivoCumbo (Alexander)
Ejecutivos de Solid Biosciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.41K
+1.22%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
146.16K
+8.65%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
141.59K
+2.43%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
105.08K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
82.81K
-43.95%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
74.32K
-46.95%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
63.78K
-52.65%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.41K
+1.22%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
146.16K
+8.65%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
141.59K
+2.43%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
105.08K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
82.81K
-43.95%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
74.32K
-46.95%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Solid Biosciences Inc?
Los cinco principales accionistas de Solid Biosciences Inc son: Mr. Alexander (Bo) Cumbo
¿Cuántas instituciones poseen acciones de Solid Biosciences Inc (SLDB)?
A fecha de 2026Q1, 271 instituciones poseen acciones de Solid Biosciences Inc, con un valor de mercado combinado de aproximadamente 83.89M, lo que representa el 85.25% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -13751546.00.